Literature DB >> 7496927

Enzyme-linked immunosorbent assay using a recombinant baculovirus-expressed Bacillus anthracis protective antigen (PA): measurement of human anti-PA antibodies.

L C Iacono-Connors1, J Novak, C Rossi, J Mangiafico, T Ksiazek.   

Abstract

We developed an antigen capture enzyme-linked immunosorbent assay (ELISA) which does not require purified protective antigen (PA) for detection of human antibodies to Bacillus anthracis PA. Lysates of Spodoptera frugiperda (Sf-9) cells infected with recombinant baculovirus containing the PA gene were used as the source of PA to develop the ELISA. Recombinant PA from crude Sf-9 cell lysates or PA purified from B. anthracis Sterne strain was captured by an anti-PA monoclonal antibody coated onto microtiter plates. We demonstrated that human serum antibody titers to PA were identical in the ELISA whether we used crude Sf-9 cell lysates containing recombinant baculovirus-expressed PA or purified Sterne PA. Finally, false-positive results observed in a direct ELISA were eliminated with this antigen capture ELISA. Thus, the antigen capture ELISA with crude preparations of baculovirus-expressed PA is reliable, safe, and inexpensive for determining anti-PA antibody levels in human sera.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7496927      PMCID: PMC368200          DOI: 10.1128/cdli.1.1.78-82.1994

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN: 1071-412X


  15 in total

1.  Large-scale production of protective antigen of Bacillus anthracis in anaerobic cultures.

Authors:  M PUZISS; L C MANNING; J W LYNCH; I ABELOW; G G WRIGHT
Journal:  Appl Microbiol       Date:  1963-07

2.  Field Evaluation of a Human Anthrax Vaccine.

Authors:  P S Brachman; H Gold; S A Plotkin; F R Fekety; M Werrin; N R Ingraham
Journal:  Am J Public Health Nations Health       Date:  1962-04

3.  Comparative efficacy of Bacillus anthracis live spore vaccine and protective antigen vaccine against anthrax in the guinea pig.

Authors:  S F Little; G B Knudson
Journal:  Infect Immun       Date:  1986-05       Impact factor: 3.441

4.  Development of antibodies to protective antigen and lethal factor components of anthrax toxin in humans and guinea pigs and their relevance to protective immunity.

Authors:  P C Turnbull; M G Broster; J A Carman; R J Manchee; J Melling
Journal:  Infect Immun       Date:  1986-05       Impact factor: 3.441

5.  Production and purification of anthrax toxin.

Authors:  S H Leppla
Journal:  Methods Enzymol       Date:  1988       Impact factor: 1.600

6.  Anthrax indirect microhemagglutination test.

Authors:  T M Buchanan; J C Feeley; P S Hayes; P S Brachman
Journal:  J Immunol       Date:  1971-12       Impact factor: 5.422

7.  Purification and properties of in vitro-produced anthrax toxin components.

Authors:  D C Fish; B G Mahlandt; J P Dobbs; R E Lincoln
Journal:  J Bacteriol       Date:  1968-03       Impact factor: 3.490

Review 8.  Anthrax: the disease in relation to vaccines.

Authors:  P Hambleton; J A Carman; J Melling
Journal:  Vaccine       Date:  1984-06       Impact factor: 3.641

9.  Immunization against anthrax with Bacillus anthracis protective antigen combined with adjuvants.

Authors:  B E Ivins; S L Welkos; S F Little; M H Crumrine; G O Nelson
Journal:  Infect Immun       Date:  1992-02       Impact factor: 3.441

Review 10.  Recent advances in the development of an improved, human anthrax vaccine.

Authors:  B E Ivins; S L Welkos
Journal:  Eur J Epidemiol       Date:  1988-03       Impact factor: 8.082

View more
  8 in total

1.  Phase II randomized, double-blinded comparison of a single high dose (5×10(8) TCID50) of modified vaccinia Ankara compared to a standard dose (1×10(8) TCID50) in healthy vaccinia-naïve individuals.

Authors:  Sharon E Frey; Patricia L Winokur; Heather Hill; Johannes B Goll; Paul Chaplin; Robert B Belshe
Journal:  Vaccine       Date:  2014-03-06       Impact factor: 3.641

2.  Attenuated nontoxinogenic and nonencapsulated recombinant Bacillus anthracis spore vaccines protect against anthrax.

Authors:  S Cohen; I Mendelson; Z Altboum; D Kobiler; E Elhanany; T Bino; M Leitner; I Inbar; H Rosenberg; Y Gozes; R Barak; M Fisher; C Kronman; B Velan; A Shafferman
Journal:  Infect Immun       Date:  2000-08       Impact factor: 3.441

3.  Determination of serum IgG antibodies to Bacillus anthracis protective antigen in environmental sampling workers using a fluorescent covalent microsphere immunoassay.

Authors:  R E Biagini; D L Sammons; J P Smith; E H Page; J E Snawder; C A F Striley; B A MacKenzie
Journal:  Occup Environ Med       Date:  2004-08       Impact factor: 4.402

4.  Comparison of a multiplexed fluorescent covalent microsphere immunoassay and an enzyme-linked immunosorbent assay for measurement of human immunoglobulin G antibodies to anthrax toxins.

Authors:  Raymond E Biagini; Deborah L Sammons; Jerome P Smith; Barbara A MacKenzie; Cynthia A F Striley; Vera Semenova; Evelen Steward-Clark; Karen Stamey; Alison E Freeman; Conrad P Quinn; John E Snawder
Journal:  Clin Diagn Lab Immunol       Date:  2004-01

5.  Inhalational anthrax outbreak among postal workers, Washington, D.C., 2001.

Authors:  Puneet K Dewan; Alicia M Fry; Kayla Laserson; Bruce C Tierney; Conrad P Quinn; James A Hayslett; Laura N Broyles; Andi Shane; Kevin L Winthrop; Ivan Walks; Larry Siegel; Thomas Hales; Vera A Semenova; Sandra Romero-Steiner; Cheryl Elie; Rima Khabbaz; Ali S Khan; Rana A Hajjeh; Anne Schuchat
Journal:  Emerg Infect Dis       Date:  2002-10       Impact factor: 6.883

6.  Specific, sensitive, and quantitative enzyme-linked immunosorbent assay for human immunoglobulin G antibodies to anthrax toxin protective antigen.

Authors:  Conrad P Quinn; Vera A Semenova; Cheryl M Elie; Sandra Romero-Steiner; Carolyn Greene; Han Li; Karen Stamey; Evelene Steward-Clark; Daniel S Schmidt; Elizabeth Mothershed; Janet Pruckler; Stephanie Schwartz; Robert F Benson; Leta O Helsel; Patricia F Holder; Scott E Johnson; Molly Kellum; Trudy Messmer; W Lanier Thacker; Lilah Besser; Brian D Plikaytis; Thomas H Taylor; Alison E Freeman; Kelly J Wallace; Peter Dull; Jim Sejvar; Erica Bruce; Rosa Moreno; Anne Schuchat; Jairam R Lingappa; Sandra K Martin; John Walls; Melinda Bronsdon; George M Carlone; Mary Bajani-Ari; David A Ashford; David S Stephens; Bradley A Perkins
Journal:  Emerg Infect Dis       Date:  2002-10       Impact factor: 6.883

7.  Development and application of a Bacillus anthracis protective antigen domain-1 in-house ELISA for the detection of anti-protective antigen antibodies in cattle in Zambia.

Authors:  Manyando Simbotwe; Daisuke Fujikura; Miyuki Ohnuma; Ryosuke Omori; Yoshikazu Furuta; Geoffrey Munkombwe Muuka; Bernard Mudenda Hang'ombe; Hideaki Higashi
Journal:  PLoS One       Date:  2018-10-18       Impact factor: 3.240

8.  Comparison of lyophilized versus liquid modified vaccinia Ankara (MVA) formulations and subcutaneous versus intradermal routes of administration in healthy vaccinia-naïve subjects.

Authors:  Sharon E Frey; Anna Wald; Srilatha Edupuganti; Lisa A Jackson; Jack T Stapleton; Hana El Sahly; Samer S El-Kamary; Kathryn Edwards; Harry Keyserling; Patricia Winokur; Wendy Keitel; Heather Hill; Johannes B Goll; Edwin L Anderson; Irene L Graham; Christine Johnston; Mark Mulligan; Nadine Rouphael; Robert Atmar; Shital Patel; Wilbur Chen; Karen Kotloff; C Buddy Creech; Paul Chaplin; Robert B Belshe
Journal:  Vaccine       Date:  2015-07-02       Impact factor: 4.169

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.